PUBLIC COMPANY
saveMemorial Sloan Kettering Cancer Center
updated 4mo ago
community read0 votes
🐶 often sniffed alongside
top 3pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
- phase2Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
- phase2Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- phase2A Study of ZEN003694 in People With Squamous Cell Lung Cancer
- phase2Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
- phase2Tislelizumab in People With Colorectal Cancer
- phase2Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
- phase1A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
🐶 Hiring Signal
News
- 5 drugmakers chasing Merck and Moderna in the cancer vaccine raceFollowing their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…biospace · 20d ago
- After a brief storm of political headwinds, mRNA is back with strong momentumA year to the day after the Trump administration slashed $500 million in funding from mRNA-based programs, the FDA approved Moderna’s flu vaccine based on the technology. Weeks later, Moderna and M…biospace · 20d ago
- Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.biospace · 26d ago
- BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancerShares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase…biospace · 1mo ago
- Amgen, academic centers weigh new FDA pilot to speed early drug trialsTo better combat China and Australia's dominance in expediting early-phase trials, the FDA and stakeholders are ironing out the details of a pilot program to accelerate first-in-human trials. Amgen…endpoints · 1mo ago
- Third time’s the charm for Replimune as melanoma drug earns FDA greenlightReplimune’s immunotherapy for advanced melanoma faced a perilous regulatory road with two previous rejections, but the drug—to be marketed as Tudriqev—prevailed with strong support from oncologists…biospace · 1mo ago
- Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapyThe FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10 to 3 in favor of Replimune’s immunotherapy for advanced melanoma in combination with Bristol Myers Squibb’s Opdivo, but tri…biospace · 2mo ago
- Dr Postow on an Ideal Post-ICI Monitoring Framework in MelanomaMichael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.onclive · 4mo ago
- Dr Postow on the Timing of Delayed or Re-Emergent irAEs in MelanomaMichael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.onclive · 4mo ago
- Dr Mauro on the Significance of Alternative TKI Formulations in CMLMichael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.onclive · 4mo ago
comments(0)
5-min edit window · permanent after that